Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

161. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome

Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

162. Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care

Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

163. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis

Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis Rahimi R, Nikfar S, Rezaie A, Abdollahi M CRD summary This review concluded that low-dose tricyclic antidepressants (TCAs) exhibited clinically and statistically significant control of irritable bowel syndrome (IBS) symptoms. Caution is warranted (...) in the application of the results as reported TCA effects may have been overestimated given the small number of studies and patients reviewed. Authors' objectives To assess the efficacy of tricyclic antidepressants (TCAs) in patients with irritable bowel syndrome (IBS). Searching PubMed, Scopus, Web of Science and Cochrane Central Register of Controlled Trials (CENTRAL) were searched (from 1966 to September 2008) for English-language papers. Search terms were reported. Reference lists of retrieved articles were

2009 DARE.

164. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review

The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS CRD summary This review evaluated efficacy, safety and tolerability of probiotics in irritable bowel syndrome and concluded that Bifidobacterium infantis 35624 showed efficacy (...) in improving symptoms; data for other probiotics were inadequate. The conclusion that evidence on probiotics was of poor quality appeared appropriate, although conclusions about the efficacy of B. infantis may be less reliable. Authors' objectives To evaluate efficacy, safety and tolerability of probiotics in treatment of irritable bowel syndrome (IBS). Searching MEDLINE, PubMed, EMBASE and The Cochrane Library were searched from inception to June 2008 to identify relevant articles published in English

2009 DARE.

165. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. Full Text available with Trip Pro

Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. To determine the effectiveness of increasing the dietary content of soluble fibre (psyllium) or insoluble fibre (bran) in patients with irritable bowel syndrome.Randomised controlled trial.General practice.275 patients aged 18-65 years with irritable bowel syndrome.12 weeks of treatment with 10 g psyllium (n=85), 10 g bran (n=97), or 10 g placebo (rice flour) (n=93).The primary end point (...) was adequate symptom relief during at least two weeks in the previous month, analysed after one, two, and three months of treatment to assess both short term and sustained effectiveness. Secondary end points included irritable bowel syndrome symptom severity score, severity of abdominal pain, and irritable bowel syndrome quality of life scale.The proportion of responders was significantly greater in the psyllium group than in the placebo group during the first month (57% v 35%; relative risk 1.60, 95

2009 BMJ Controlled trial quality: predicted high

166. Psychological treatments may be effective for managing irritable bowel syndrome

Psychological treatments may be effective for managing irritable bowel syndrome PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Psychological treatments may be effective for managing irritable bowel syndrome Clinical question How effective are psychological interventions for the treatment of irritable bowel syndrome (IBS)? Bottom line Psychological interventions (cognitive behavioural therapy (...) of irritable bowel syndrome. Cochrane Reviews 2009, Issue 1. Article No: CD006442. DOI: 10.1002/14651858.CD006442.pub2. This review contains 25 studies involving 1858 participants. PEARLS 156, April 2009, written by Brian R McAvoy [References] 1. Drossman DA et al. Gastroenterology 1997;112:2120-2137 are funded by the New Zealand Guidelines Group. PEARLS provide guidance on whether a treatment is effective or ineffective. PEARLS are prepared as an educational resource and do not replace clinician judgement

2009 Cochrane PEARLS

167. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. Full Text available with Trip Pro

Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. To determine the effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome.Systematic review and meta-analysis of randomised controlled trials.Medline, Embase, and the Cochrane controlled trials register up to April 2008. Review methods Randomised controlled trials comparing fibre, antispasmodics, and peppermint oil (...) with placebo or no treatment in adults with irritable bowel syndrome were eligible for inclusion. The minimum duration of therapy considered was one week, and studies had to report either a global assessment of cure or improvement in symptoms, or cure of or improvement in abdominal pain, after treatment. A random effects model was used to pool data on symptoms, and the effect of therapy compared with placebo or no treatment was reported as the relative risk (95% confidence interval) of symptoms persisting

2008 BMJ

168. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome Full Text available with Trip Pro

Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome The intestinal permeability is increased in patients with diarrhoea-predominant irritable bowel syndrome (D-IBS).To determine the possible efficacy of lactic acid bacteria on the increased intestinal permeability in D-IBS.Treatment was employed for 4 weeks in a randomized single blind placebo controlled study with 30 D-IBS patients. Patients were (...) given either probiotic fermented milk (Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus acidophilus and Bifidobacterium Longum) or milk beverage containing no bacteria. The clinical symptoms were scored and intestinal permeability was measured by a triple sugar test before and after treatment.Small bowel permeability was measured as the ratio of lactulose and mannitol recovery and colonic permeability was measured as the total mass of sucralose excretion (mg). After probiotics

2008 EvidenceUpdates Controlled trial quality: uncertain

169. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome Full Text available with Trip Pro

Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome In models of irritable bowel syndrome (IBS), asimadoline, a kappa-opioid agonist, improves pain and abnormal bowel function.To evaluate the effects of three doses of asimadoline and placebo in subjects with IBS through a double-blind, randomized, placebo-controlled trial.Patients were randomly assigned to receive asimadoline 0.15, 0.5, 1.0 mg or placebo BID for 12 weeks. The primary efficacy measure

2008 EvidenceUpdates Controlled trial quality: predicted high

170. Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents (Abstract)

Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents To determine the efficacy of amitriptyline (AMI) in treating irritable bowel syndrome (IBS) in adolescents.Adolescents 12 to 18 years with newly diagnosed IBS were surveyed with a symptom checklist, pain rating scale, visual analog scale, and IBS quality of life (QOL) questionnaire. Subjects were randomized in a double-blinded fashion to receive AMI or placebo, and again completed

2008 EvidenceUpdates Controlled trial quality: predicted high

171. Effectiveness of probiotics in the treatment of irritable bowel syndrome Full Text available with Trip Pro

Effectiveness of probiotics in the treatment of irritable bowel syndrome Recently, the use of tegaserod and alosetron -- drugs approved for the treatment of irritable bowel syndrome (IBS) -- has been restricted because of adverse events. This has resulted in a need for additional modalities for the treatment of IBS. Our objective was to determine the effectiveness of probiotics in the global relief of symptoms associated with IBS and in the improvement of flatulence, abdominal pain, transit

2008 EvidenceUpdates

172. Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review Full Text available with Trip Pro

Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review Irritable bowel syndrome (IBS) is a common disorder that occurs in adults. The natural history of symptoms and risk factors that contribute to IBS may begin in childhood. The aim of this systematic review was to determine what early life factors contribute to the development of IBS in adolescents and adults.A computer-assisted search of the PubMed database from 1966 to 2007 was performed

2008 EvidenceUpdates

173. Psychosocial interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. (Abstract)

Psychosocial interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Between 4% and 25% of school-age children complain of recurrent abdominal pain (RAP) of sufficient severity to interfere with daily activities. For the majority of such children, no organic cause for their pain can be found on physical examination or investigation. Although most children are managed by reassurance and simple measures, a large range of psychosocial interventions

2008 Cochrane

174. Irritable bowel syndrome in adults: diagnosis and management

Irritable bowel syndrome in adults: diagnosis and management Irritable bowel syndrome in adults: Irritable bowel syndrome in adults: diagnosis and management diagnosis and management Clinical guideline Published: 23 February 2008 nice.org.uk/guidance/cg61 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived (...) be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Irritable bowel syndrome in adults: diagnosis and management (CG61) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2008 National Institute for Health and Clinical Excellence - Clinical Guidelines

175. Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome

Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 NHS Economic Evaluation Database.

176. Meta-analysis of probiotics for the treatment of irritable bowel syndrome Full Text available with Trip Pro

Meta-analysis of probiotics for the treatment of irritable bowel syndrome Meta-analysis of probiotics for the treatment of irritable bowel syndrome Meta-analysis of probiotics for the treatment of irritable bowel syndrome McFarland LV, Dublin S CRD summary This review concluded that probiotic use may be associated with improvement in irritable bowel syndrome symptoms compared to placebo, but these results should be interpreted with caution. This cautious conclusion accurately reflects (...) the nature of the evidence and the results of the review, and appears likely to be reliable. Authors' objectives To determine the overall efficacy of probiotics in the treatment of irritable bowel syndrome (IBS). Searching MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), and C databases and Google Scholar were searched. Reference lists of identified studies, reviews, commentaries, books and meeting abstracts were searched. Search terms were reported. Studies published in full

2008 DARE.

177. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials

Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

178. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials

Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

179. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized controlled trials

Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

180. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms?

Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? Ford A C, Talley N J, Velhuyzen van Zenten (...) S J, Vakil N B, Simel D L, Moayyedi P CRD summary This review assessed the ability of components of clinical history and physical examination (alone or in combination) to predict a diagnosis of irritable bowel syndrome (IBS) without full investigation of the lower GI tract. The authors' conclusion that individual symptoms and existing diagnostic criteria have only moderate accuracy was a reasonable interpretation of the limited data available. Authors' objectives To determine the accuracy

2008 DARE.